Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.49
+0.13001.25%
Post-market: 10.540.0500+0.48%19:30 EDT
Volume:1.52M
Turnover:15.77M
Market Cap:2.30B
PE:-7.42
High:10.54
Open:10.30
Low:10.13
Close:10.36
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.89
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.42
PE(LYR):-7.39

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Twist Bioscience (TWST)

TIPRANKS
·
Aug 04

Ocular Therapeutix Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Reuters
·
Aug 03

Design Therapeutics Q2 Net Loss Narrower than Expected

Reuters
·
Aug 03

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

Reuters
·
Aug 03

Ocular Therapeutix Q2 Product Revenue USD 13.48 Million

THOMSON REUTERS
·
Aug 03

Earnings Flash (OCUL) Ocular Therapeutix Posts Q2 Net Loss $0.35 a Share, vs. FactSet Est of $0.40 Loss

MT Newswires Live
·
Aug 03

Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate

Benzinga Earnings
·
Aug 03

Ocular Therapeutix Q2 FY26 Net Loss Widens to $78.76 Million; Revenue Rises 0.12% to $13.48 Million

Reuters
·
Aug 03

Ocular Therapeutix Grants New Hires Options for 34,700 Shares at $9.66 Each

Reuters
·
Jul 10

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 10

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 10

OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market

TIPRANKS
·
Jul 02

Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)?

Simply Wall St.
·
Jul 01

Ocular Therapeutix to Present at ASRS Annual Meeting

Reuters
·
Jul 01

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

GlobeNewswire
·
Jul 01

Ocular Therapeutix is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 25

Chardan Raises Price Target on Ocular Therapeutix to $23 From $21, Keeps Buy Rating

MT Newswires Live
·
Jun 25

Ocular Therapeutix grants new SVP inducement awards of 85,000 stock options, 28,000 RSUs

Reuters
·
Jun 23

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 23